More baby milk recalls in France after new toxin rules

Weather - Sydney 11°C

More baby milk recalls in France after new toxin rules

ECONOMY 02.02.2026

More baby milk recalls in France after new toxin rules / Photo: © AFP

Two infant formula manufacturers withdrew batches from the market on Monday after France imposed stricter limits on acceptable levels of a toxin that can cause nausea, vomiting and diarrhoea.

Change text size:

French maker Popote said it was recalling two lots, while Vitagermine removed three different batches of Babybio formula from the shelves in the latest such recalls to rock the infant formula industry in recent weeks.

Several manufacturers, including European giants like Nestle, Danone, and Lactalis, have issued recalls of infant formula that could be contaminated with cereulide in more than 60 countries since December.

French authorities are investigating the deaths in December and January of two babies who were thought to have drunk possibly contaminated powdered milk. No link has been established so far between the formula and their symptoms.

The agriculture ministry on Friday set the new threshold at 0.014 micrograms of cereulide per kilogram of body weight, instead of 0.03 micrograms.

Vitagermine said its milk had complied with French rules until they changed last week, and it was removing the three batches on Monday to "better ensure the safety of infants".

Popote said it was removing two batches of first-stage infant formula "without waiting for the new European framework".

The European Food Safety Authority (EFSA) on Monday said its scientists had also suggested a maximum level for cereulide of 0.014 micrograms per kilogram of body weight.

This translated to 0.054 micrograms of cereulide per litre in infant formula, the Italy-based agency said.

"This advice is intended to help EU risk managers determine when products should be withdrawn from the market as a precautionary public health measure," it added.

- Cereulide health risk -

But European consumer association Foodwatch accused multinationals of focusing on thresholds as a "diversionary tactic".

"Cereulide should not be there at all in the first place," it said.

"It is illegal to market products that expose babies to health risks," it added, comparing cereulide to mouse droppings.

"There is no European standard on the presence of mouse droppings in infant formula. Nevertheless, it is prohibited," Foodwatch said.

The recall of potentially contaminated infant formula has heaped scrutiny on Chinese firm Cabio Biotech, the supplier of an ingredient used in infant formula which is suspected of being tainted.

Headquartered in the central Chinese city of Wuhan, Cabio Biotech is one of the world's largest producers of ARA, a fatty acid used primarily in baby formula and food products.

French company Nutribio told AFP it recalled some of its milk following an "alert" from Cabio Biotech.

French advocacy group Children's Health also named the company in a court filing, asking the government to order companies to pull all formula with ARA oil produced by Cabio Biotech.

Cabio Biotech has yet to publicly address allegations its ARA oil was contaminated, and has not responded to multiple requests for comment.

P.Sinclair--TNT

Featured

Nearly 1,100 flights cancelled after UK air traffic control glitch

Almost 1,100 flights to and from UK airports were cancelled Tuesday due to what the country's air traffic control service called a technical issue, in the latest glitch to spark travel chaos.

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Change text size:

The National Times - More baby milk recalls in France after new toxin rules